Vimian Group (VIMIAN) Q3 2025 earnings summary

Executive summary

• Achieved 19% revenue growth and 9% organic growth in Q3 2025, with strong performance in Specialty Pharma and Veterinary Services, and MedTech returning to organic growth despite a soft US market.

• Adjusted EBITA/EBITDA increased by 17% to EUR 25.5m, with a margin of 24.5%, reflecting investments in MedTech and consolidation of dental business iM3.

• Net result improved to EUR 6.8m from a loss of EUR -1.9m in Q3 2024; EPS was EUR 0.01.

• Secured a USD 40.2m court award in a US indemnification dispute, with the first USD 15m payment received post-quarter.

• CEO transition occurred in July, with an interim CEO appointed.

Financial highlights

• Q3 2025 revenue reached EUR 104.3m (+19% y/y), with 9% organic growth and a 4% negative currency impact.

• Adjusted EBITA/EBITDA margin was 24.5% (down from 25.0% last year), mainly due to investments and business mix.

• Operating profit (EBIT) rose 74% year-over-year to EUR 17.5m.

• Net profit for the period was EUR 6.8m; EPS was EUR 0.01.

• Cash flow from operations was EUR 10.8m, impacted by higher tax expenses and FX.

Outlook and guidance

• Specialty Pharma expected to maintain double-digit organic growth into 2026, supported by strong momentum and product launches.

• Continued focus on strengthening U.S. MedTech commercial performance, expanding M&A pipeline, and leveraging strong market positioning.

• Ongoing investments in commercial capabilities, with a focus on like-for-like margin improvement.

• Market growth drivers include rising pet ownership, insurance penetration, and pet humanization.

• MedTech segment expected to face a soft US surgery market in the near term, but long-term prospects remain positive.